TL;DR
A University of Florida study found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Mouse and human brain tissue experiments point to a possible metabolic mechanism, but the findings do not show that the supplement causes worsening and need testing in a human clinical trial.
Researchers at the University of Florida reported that glucosamine use was associated with a 25% higher likelihood that mild cognitive impairment would progress to dementia, raising questions about a widely used joint supplement. The retrospective health-record analysis, published in Nature Metabolism, does not establish that glucosamine causes the progression; supporting experiments in mouse models and human brain tissue point to a possible biological pathway.
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The research team used artificial intelligence to analyze deidentified UF Health records from 2012 to 2024. It examined people diagnosed with Alzheimer’s disease and related dementias, or ADRD, and people with mild cognitive impairment, a measurable decline in memory or thinking that may not substantially disrupt daily life. In each group, 8% reported glucosamine use: 1,896 people with ADRD and 2,750 with MCI.
After accounting for age, sex and demographics, glucosamine use was associated with a 25% higher likelihood of MCI progressing to dementia. Among people already diagnosed with ADRD, use was also associated with a 25% higher mortality risk during the study’s defined observation period. The researchers did not see this mortality association in the MCI group. These are associations from patient records, and the report does not give a basis for interpreting the percentages as absolute risk increases.
The researchers investigated a process called glycosylation, in which sugar structures attach to proteins. In genetically modified mice, glucosamine increased this attachment and treated animals had worse social-memory deficits than other mice. A chemical treatment that suppressed the process improved the mice’s memory performance. Human brain specimens from people with Alzheimer’s showed more sugar attachment than specimens from controls. These experiments support a possible mechanism, but they do not establish what glucosamine does to disease progression in people.
A Common Supplement Raises Questions
Glucosamine is sold over the counter and is commonly used by older adults for joint discomfort or joint health. That widespread use gives the finding potential relevance for people with cognitive impairment and those involved in their care. The study raises a question about whether the supplement could interact with disease-related changes in the brain, but it does not show that taking glucosamine causes dementia to worsen.
The work also adds to research examining metabolic processes alongside the amyloid plaques and tau tangles often associated with Alzheimer’s disease. Senior author Ramon Sun said the findings suggest that altered metabolism may contribute to progression and could eventually complement research focused on plaques and tangles. That is a research implication, not an established treatment approach.
Co-author Matt Gentry said the electronic-record findings were “very provocative,” while stressing that association is not proof of causality. His distinction matters: the human data identify a signal for further study, while the laboratory experiments offer a possible explanation that still needs evaluation in people.
Products Worth Considering
Withings Sleep Under-Mattress Sleep Tracking Pad
Fitbit Versa 4 Health and Fitness Smartwatch with GPS, Heart Rate and Sleep Tracking, Alexa, Water Resistant, Black
Withings ScanWatch Light Hybrid Smartwatch, Black
As an affiliate, we earn on qualifying purchases.
From Health Records to Brain Tissue
The team’s analysis drew on records of patients with ADRD or MCI treated at UF Health between 2012 and 2024. Researchers worked with Yi Guo and Jiang Bian on the health-record analysis. The study was published in Nature Metabolism in 2026 under the title “Hyperglycosylation is a metabolic driver of Alzheimer’s disease.”
Glucosamine is a naturally occurring, sugar-related molecule that can cross the blood-brain barrier, according to the researchers. Once in the brain, it can enter pathways that make complex sugar structures and attach them to proteins. The authors suggest a brain affected by Alzheimer’s may respond differently from a healthy brain to the same molecule. Their spatial analysis technology mapped molecules and metabolic pathways in brain tissue, while the mouse and tissue experiments examined the proposed process in more detail.
Alzheimer’s research has often focused on amyloid beta deposits between brain cells and twisted tau proteins inside neurons. The study considers whether an overactive sugar-tagging process may also be involved. Its findings support further investigation into metabolism, but the human record analysis and laboratory evidence answer different questions and should not be treated as proof of a direct supplement effect in patients.
““While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention.””
— Matt Gentry, study co-author and chair of UF’s Department of Biochemistry and Molecular Biology
Cause and Patient Risk Remain Unknown
The record analysis cannot determine whether glucosamine itself contributes to faster progression or whether other differences between supplement users and nonusers help explain the association. The report does not establish the absolute likelihood of progression for an individual patient, nor does it identify which people might be more vulnerable. The mortality association appeared in the ADRD group but not the MCI group; the available findings do not explain that difference.
Mouse memory experiments and human brain tissue findings provide evidence about a possible mechanism, but they cannot show that supplement use accelerates dementia in people. A controlled human clinical trial would be needed to test causality and clarify which patients, if any, face a measurable risk. The study does not establish that people should stop taking glucosamine. Anyone weighing supplement use alongside cognitive impairment or dementia should discuss personal decisions with a qualified health professional.
Human Trials Are the Next Test
The next major step identified by the researchers is a controlled clinical trial in people. Such a study could test whether glucosamine changes Alzheimer’s or related dementia progression, rather than simply occurring alongside it, and help determine whether effects vary among patients. Until that evidence is available, the reported link remains preliminary. The study’s authors also point to the sugar-tagging pathway as a potential subject for future research; whether it can guide treatment remains undetermined.
Key Questions
Does this study prove glucosamine causes dementia to progress?
No. The health-record analysis found an association, which cannot establish that glucosamine caused the progression. A controlled human clinical trial is needed to test cause and effect.
What did the researchers find about mild cognitive impairment?
Glucosamine use was associated with a 25% higher likelihood that MCI would progress to dementia in the analyzed records, after the researchers accounted for age, sex and demographics. The report does not provide an absolute risk increase for an individual.
Did the study find a link with mortality?
Among people already diagnosed with ADRD, glucosamine use was associated with a 25% higher mortality risk during the defined observation period. The researchers did not observe that association in the MCI group.
Should people stop taking glucosamine?
The findings do not establish that people should stop taking the supplement. Anyone with cognitive impairment or dementia who has questions about glucosamine should discuss their circumstances with a qualified health professional.
What research is needed next?
A controlled human clinical trial is needed to test whether glucosamine directly affects disease progression and identify which patients, if any, may be vulnerable. The reported mouse and brain tissue experiments suggest a possible mechanism but do not resolve those questions.
Source: rss
